stockrowDBV Technologies S.A.
DBVT Healthcare Biotechnology
DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
- Revenue
- −42.9%
- EPS
- +40.4%
- Free cash flow
- −64.9%
Quarter to September 2026, against a year earlier
Follow DBVT
Alert me
DBV Technologies S.A. (DBVT) EV/Sales
As of 6 November 2026, DBV Technologies S.A. (DBVT) trades at a EV/Sales of 211×. Over the past ten years it has ranged from −2.6× (December 2023) to 329× (October 2021); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 60.5× | 808.15% |
| FY2024 | 6.7× | 168.98% |
| FY2023 | 2.5× | (48.12%) |
| FY2022 | 4.8× | (72.35%) |
| FY2021 | 17.3× | 122.29% |
| FY2020 | 7.8× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 240× | (5.16%) |
| Jun 2026 | 253× | (7.11%) |
| Mar 2026 | 272× | 349.49% |
| Dec 2025 | 60.5× | 66.50% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | 1.7× |
| GERN Geron Corporation compare | 2.6× |
| ZVRA Zevra Therapeutics, Inc. compare | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| DBVT DBV Technologies S.A. | 211× |
| DSGN Design Therapeutics, Inc. compare | 1,919× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)